GAJ - HIV DART 2008 Presentations






		HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies Click here to view the complete abstract book Selected Slide Presentations Click on the links below to view presentations. Pathogenesis and Targeted Design Understanding HIV Maturation using Electron Cryotomography Elizabeth Wright, California Institute of Technology, USA Diminution of HIV Latency through Blockage of Arginine Methylation of Viral Proteins Mark Wainberg, McGill University AIDS Centre, Canada Oral Abstract Session I Immunotoxins to Selectively Deplete Reservoirs of HIV-infected Cells that Persist in the Face of Highly Suppressive Antiretroviral Therapy Edward Berger, National Institutes of Health, USA Development of Pyrimidinedione NNRTIs with a High Genetic Barrier to Resistance Robert Buckheit, ImQuest BioSciences, USA Development of VS411, a Virostatic Drug Fixed Dose Combination (FDC) Designed to Inhibit both HIV and Immune Hyperactivation Mike Stevens, ViroStatics Srl, Italy Inhibiting Vpu Function with the Novel Compound BIT225, Results in Inhibition of HIV-1 Release from Human Macrophage Reservoirs John Wilkinson, Biotron Limited, Australia Toward HIV Eradication II State of the Art Lecture Integrase Inhibitors: New Insights into Mechanism of Action and Pharmacology with Implications for Treatment and Prevention Strategies Daria Hazuda, Merck Research Labs, USA A Non-human Primate Model for Development of AIDS Eradication Strategies Thomas North, University of California, Davis, USA Prevention and Drug Resistance David Barry DART Achievement Award Milestones in HIV Drug Resistance: From in Vitro to in Silico Brendan Larder, HIV Resistance Response Database Initiative (RDI), UK HIV Therapy in Developing Countries Experiences in HIV Treatment in Developing Countries Ian Sanne, Wits Health Consortium, South Africa To Wean or not to Wean: Prevention of Mother-to-child Transmission through Breast Milk Charles van der Horst, University of North Carolina at Chapel Hill, USA Oral Abstract Session II Glycan Deletions in the HIV-1 gp120 V1/V2 Domain Compromise Viral Infectivity, Sensitize the Mutant Virus Strains to Carbohydrate Binding Agents and Represent a Specific Target for Therapeutic Intervention Joeri Auwerx, K.U. Leuven, Rega Institute for Medical Research, Belgium Safety, Tolerability and Efficacy of Darunavir/ritonavir in Treatment-experienced Women with HIV Infection: Interim Analysis of GRACE (Gender, Race, and Clinical Experience) Carmen Zorrilla, University of Puerto Rico School of Medicine, USA HIV/Hepatitis and Other Co-infections State of the Art Lecture The Aging Liver in the HIV Population Douglas Dieterich, Mount Sinai School of Medicine, USA Co-infection with HCV and HBV: When and How to Treat? Bruce Polsky, St. Luke's Roosevelt Hospital Center, USA Novel Therapeutic Approaches: Antiviral Mechanism and Predictive Toxicology State of the Art Lecture Optimizing HAART Therapy in the Era of Integrase and Entry Inhibitors Christine Katlama, Hôpital Pitié-Salpêtrière, France IDX-899 -- A Novel Once-a-day Second Generation NNRTI for the Treatment of HIV/AIDS Douglas Mayers, Idenix Pharmaceuticals, Inc., USA Vicriviroc: A Next Generation CCR5 Antagonist for Treatment of HIV Lisa Dunkle, Schering-Plough Research Institute, USA Amdoxovir Combined with Low Dose AZT for HIV-1 Therapy Robert Murphy, Northwestern University, USA Low Potential for Class Related Toxicity of Next Generation Nucleotide Analog GS-9148 Adrian Ray, Gilead Sciences, Inc., USA Mechanisms Associated with Delayed HIV RT Chain-termination Matthias Götte, McGill University, Canada Oral Abstract Session III Special Lecture Acyclovir as an HIV-1 RT Inhibitor in Herpesvirus-infected Human Tissues Leonid Margolis, National Institute of Child Health and Human Development, USA Comparison of Two Human Pancreatic Cell Lines for Predicting Mitochondrial Toxicity by Nucleoside Analogs Leda Bassit, Emory University School of Medicine and VA Medical Center, USA ARTEMIS: Efficacy and Safety of Darunavir/ritonavir (DRV/r) 800/100 mg Once-daily vs. Lopinavir/ritonavir (LPV/r) in Treatment-naïve, HIV-1-infected Patients at 96 Weeks Dushyantha Jayaweera, University of Miami, USA Pharmacokinetics and Short-term Safety and Efficacy of Once-daily Etravirine Without and With Once-daily Darunavir/ritonavir in Antiretroviral-naïve HIV-1 Infected Adults James Witek, Tibotec Therapeutics, USA Late Breaker Presentations Genome-scale RNAi Screen for Host Factors Required for HIV Replication Amy Espeseth, Merck & Co., Inc., USA Antiviral Activity and Tolerability of PRO 140, a Humanized Monoclonal Antibody to CCR5 Stephen Morris, Progenics Pharmaceuticals, Inc., USA